Cumulatively, the alterations in phospho-targets and CD44 expression following treatment in vivo largely mirror those observed in vitro and suggest that both PD901 and rapamycin exert expected on-target effects on tumor cells in vivo and that compensatory activation of non-targeted pathways, which is pronounced in MOC2, can be reversed with combination therapy. This evidence concerns the gene CD44 and neoplasm.